Economic Development

Kailos Genetics to announce results from fourth quarter R&D initiatives at JP Morgan Healthcare Conference

News Outlet: 
Kailos Genetics
Date published: 
December 21, 2011

Kailos Genetics, a company focused on putting genetics into practice through its proprietary targeted enrichment technology, announced today that it will attend the 30th Annual JP Morgan Healthcare Conference to announce results from its fourth quarter R&D initiatives.

 

Brian Pollock, Kailos Genetics CEO, commented: “While we saw early interest in this proprietary targeted enrichment technology, our goal this quarter as a company was to optimize our platform’s performance – both in terms of the number of unique amplicons that could be tested in a single tube, to reducing workflow time – while maintaining the high specificity seen with this technology. JP Morgan provides us an opportunity to update the many companies that have engaged us in discussions to date.”

To read the rest of the story from Kailos Genetics, click here

EGEN collaborates with Nanotechnology Characterization Laboratory on brain cancer therapy

News Outlet: 
PRNewswire
Date published: 
September 26, 2011

EGEN, Inc. is collaborating with the National Cancer Institute's Nanotechnology Characterization Laboratory in Frederick, Md., to accelerate human clinical testing of a nanotechnology-based gene therapy for brain cancer.

 

EGEN's candidate gene therapy -- which  relies on nanoparticles for effective delivery to the tumor site -- is already being evaluated in Phase I and II clinical trials in patients with colorectal and ovarian cancers. EGEN is seeking to begin Phase I trials against glioblastoma, a brain cancer that is difficult to treat.

 

Microarrays Inc. launches new MI PathArray assays for studying targeted biological pathways

News Outlet: 
PRWeb
Date published: 
October 19, 2011

Microarrays Inc. (MI) launches its new MI PathArray assays for studying targeted biological pathways. These pathway-centric arrays provide the highest microarray sensitivity in the form of more sharply focused research-specialty arrays, in a multi-assay format. The MI PathArray assays bring a fresh research tool to laboratories involved in the exploration of biological pathways.

 

Partnerships in the Life Sciences

News Outlet: 
Urban Land
Date published: 
September 20, 2011

HudsonAlpha Institute among featured projects

by Ron Nyren

Collaboration is the watchword in contemporary life sciences facilities.  Even as scientists from a variety of disciplines share knowledge in pursuit of new treatments for diseases, municipal governments are pooling resources with the private sector to create biotechnology clusters, universities are teaming with nonprofit companies and nonprofit organizations are working with for-profit companies to speed the "bench to bedside" process -- getting the results of research translated into therapies that start healing people as soon as possible.

Go here for the rest of the article.

Patent approved for HudsonAlpha Institute

Han lab turns out first patent for institute

HUNTSVILLE, Ala. -The HudsonAlpha Institute for Biotechnology has been awarded a patent for a new, rapid response method to detect pathogens from clinical samples. The method— amplicon rescue multiplex polymerase chain reaction for amplification of multiple targets— is highly sensitive and as the name implies, can differentiate between pathogens that symptomatically display very similarly among populations. It is the first patent awarded for institute-generated intellectual property.
 

Q&A with Sameer Singhal, Division Director for CFD Research Corporation

News Outlet: 
42: The answer to your technology questions
Date published: 
June 15, 2011
Download PDF: 

42 Contributing Writer Mike Kelley spoke with Sameer Singhal, a Division Director at CFD Research Corporation in Cummings Research Park. A Huntsville native, he grew up in Jones Valley and met his wife Ruchi, an Atlanta native, at Georgia Tech. Sameer and Ruchi make their home in the Hampton Cove area of Huntsville.

Gov. Robert Bentley takes part in latest HudsonAlpha groundbreaking

News Outlet: 
The Huntsville Times
Date published: 
June 15, 2011

HUNTSVILLE, Ala. - The way Huntsville Mayor Tommy Battle figures it, the state's $10 million investment into Cummings Research Park could have a ripple effect.

Gov. Robert Bentley has vowed not to receive a paycheck until the state unemployment rate, currently at 9.3 percent, drops to 5 percent. Using state dollars to fund an 88,000-square-foot building on the HudsonAlpha Institute for Biotechnology campus, however, is expected to generate jobs.

Serina Therapeutics, Inc. closes $9.5 million financing round

News Outlet: 
PR Newswire
Date published: 
June 1, 2011

HUNTSVILLE, Ala., June 1, 2011 /PRNewswire/ -- Serina Therapeutics, Inc. President and CEO Randall Moreadith, MD, PhD, reported today that Serina has closed on a $9.5 million financing round to advance its lead oncology candidate SER-203 into a Phase I study in humans in early 2012.

Serina Therapeutics awarded patent for its core polymer drug delivery technology

News Outlet: 
Pharmalive.com
Date published: 
May 20, 2011

HUNTSVILLE, Ala., May 20, 2011 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology. The patent entitled "Polyoxazoline and compositions comprising the same" (U.S. Patent No. 7,943,141) covers the synthesis and composition of polyoxazolines for the delivery of different drug molecules.

Syndicate content